Zhang Ya-Li, Zhang Xiao, Miao Xiang-Zhen, Yuan Yan-Yan, Gao Jian, Li Xia, Liu Yong-Gang, Tan Peng
School of Chinese Materia Madica, Beijing University of Chinese Medicine, Beijing 100029, China.
Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing 100101, China.
J Asian Nat Prod Res. 2020 May;22(5):452-463. doi: 10.1080/10286020.2019.1585820. Epub 2019 May 23.
The effects of coptisine against advanced stage of human pancreatic carcinoma PANC-1 cells was investigated . Coptisine (25-150 μM) treatment for 48 h caused dose-dependent cell growth inhibition by using CCK-8 assay. Additionally, coptisine was found to inhibit PANC-1 cells metastasis by the wound healing assay. Flow cytometry data indicated that coptisine (25-100 μM) exhibited dose-dependent G1 phase arrest and moderate reduction of S phase. Coptisine was also found to inhibit ERK phosphorylation and total ERK levels. Our research suggested that coptisine would be a potential therapeutic drug for the treatment of pancreatic cancer.
研究了黄连碱对人胰腺癌PANC - 1细胞晚期的作用。采用CCK - 8法检测，黄连碱（25 - 150μM）处理48小时可引起剂量依赖性的细胞生长抑制。此外，通过伤口愈合试验发现黄连碱可抑制PANC - 1细胞转移。流式细胞术数据表明，黄连碱（25 - 100μM）呈现剂量依赖性的G1期阻滞，并使S期适度减少。还发现黄连碱可抑制ERK磷酸化和总ERK水平。我们的研究表明，黄连碱可能是一种治疗胰腺癌的潜在治疗药物。
